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Abstract
Background—Exposure to antineoplastic drugs confers health risks to workers, yet little is 
known about the exposure after a drug spill. Nor has the relationship between exposure and 
organizational factors such as staffing and work environment been studied.
Objective—To evaluate drug spills prospectively using biological measures and correlate drug 
spills with organizational factors.
Methods—Prospective questionnaires with 8-hour timed urine samples were collected from 
nursing and pharmacy personnel who reported a drug spill in one academic health center's infusion 
center. Urine was collected similarly from workers who did not report a spill. Liquid 
chromatography tandem mass spectrometry techniques identified detectable drug levels. After the 
prospective sampling period, workers were surveyed on workloads, practice environment, and 
safety behaviors.
Results—From 81 eligible individuals, 40 participated in the prospective study and 19 completed 
retrospective questionnaires. Four spills were reported by 9 personnel as multiple employees were 
exposed to drug spills. Four participants who reported a spill showed detectable levels of 
antineoplastic drugs. Four participants who did not report a spill had detectable levels of 
docetaxel. Compared with respondents who did not report a spill, collegial relations with 
physicians were significantly poorer for workers who reported spills.
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Conclusions—The study protocol successfully captured drug spill reports and biological 
samples. Workers have detectable levels of antineoplastic drugs through both drug spills and 
environmental contamination.
Introduction
For three decades, researchers have documented the adverse effects of hazardous drug 
exposure.1-5 Antineoplastic drugs (ADs) are among the most commonly used hazardous 
drugs identified as carcinogenic by the International Agency for Research on Cancer 
(IARC).6-7 Governmental bodies8 and professional associations9-10 have published 
guidelines on safe handling of ADs, yet guideline adoption is suboptimal.11 These same 
guidelines have not determined what drug dosages are correlated with health effects. 
Instead, the guidelines recommend that preventive measures be taken to reduce exposure 
risk.9-10 Research efforts have focused on AD exposure assessment and on process 
developments to reduce exposure, primarily through closed-system transfer devices and 
personal protective equipment. AD exposures have been monitored through environmental 
sampling of surface contamination.12-15 Prospective biological monitoring from humans has 
been confined to spot urine samples with limited evidence of uptake.16 Innovative methods 
have been developed to determine specific urine concentrations of ADs and drug 
metabolites. These methods have been validated using highly sensitive liquid 
chromatography electrospray ionization tandem-mass spectrometry to analyze urine 
samples.17 These techniques enable prospective studies to examine drug exposure.
Few published studies have examined the relationship between organizational factors and 
AD exposure. A 2010 study18 reported 16.9% of surveyed oncology nurses reported dermal 
or eye exposure to ADs. Self-reported exposures were significantly more likely to occur 
with poorer nurse staffing levels and decreased performance of two-nurse chemotherapy 
dosing verification. In addition to adequate staffing, safety behaviors may play an important 
role in mitigating risk to employees.
AD exposure remains a prevalent problem in oncology settings, limited data are available on 
acute exposures (i.e., spills of ADs), and prior studies have focused on surveillance and 
retrospective data collection. The pilot study reported below studies AD exposure 
prospectively, includes survey reports and biological measures, and explores organizational 
factors that may influence acute exposures.
Methods
Our study used prospective questionnaires linked to urine samples followed by a 
retrospective survey to address three research questions: (1) what is the context in which AD 
spills occur in ambulatory oncology settings, (2) do workers who report AD spills have 
detectable drug levels, and (3) what organizational factors are associated with AD spills? 
The institutional review boards of the principal investigator's institution and the participating 
facility approved the research protocol and all participants completed written informed 
consent.
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Nurses, medical assistants (MA), pharmacists, and pharmacy technicians employed in the 
ambulatory oncology department at one academic medical center were eligible to 
participate. These employee groups were selected as they have the most frequent contact 
with ADs and they process multiple doses throughout a shift. To avoid contamination of 
biological results, exclusion criteria were current tobacco use and current or past receipt of 
antineoplastic drugs. Study personnel attended scheduled staff meetings to present protocol 
information to eligible participants. Incentives of $20 gift cards were provided to all eligible 
participants without obligation.
The participating institution was a large academic medical center with an average daily 
volume of 100 adult infusion patients. During the six months of prospective data collection, 
the pharmacy prepared 19, 284 doses of antineoplastic drugs. Employees completed an 
annual web-based competency on hazardous drug handling policies. Standard practices 
included: drug preparation in an immediate use pharmacy with a biological safety cabinet, 
infusion tubing primed with compatible fluid (as opposed to the hazardous drug), tubing 
connections secured with a closed-system transfer device, and provision of personal 
protective equipment and chemotherapy spill kits throughout the workspace. Prior to leaving 
the pharmacy, personnel wiped each chemotherapy bag with alcohol. The personal 
protective equipment available included KC500 Purple Nitrile Gloves (with tested 
impermeability to 27 ADs) and Covidien Kendall™ CT5101 impermeable protective gowns. 
Nursing staff were instructed to keep drugs in the labeled pharmacy bags until the drug was 
connected to intravenous tubing. The occupational health department offered medical 
surveillance to all employees. The institution conducted commercially-available biannual 
surface swipe testing to evaluate environmental contamination.
Prospective Questionnaire
Prospective data collection occurred over a 6-month period. Participants were instructed to 
complete a questionnaire when a “spill, drip, drop, or leak of chemotherapy” occurred. The 
following data were requested: drug name(s), estimated spill volume (in mLs), geographic 
location of spill, number of employees involved in the spill, dermal or eye contact with the 
agent, the elements of personal protective equipment worn (gown, gloves, eye protection, 
respirator), their perceived concern over the spill on a 6-point Likert scale (strongly 
unconcerned – strongly concerned), and the use of a closed system transfer device. 
Participants could provide open-text comments about the spill. Study personnel sent 
participants monthly email reminders to report drug spills. The reminders included a link to 
the prospective questionnaire. The questionnaire link was also placed on the facility's 
internal homepage.
Urine Collection and Sampling
We replicated a previously-published protocol for prospective urine collection.16 All 
participants provided 8 hours of urine. Because our study focused on assessing exposures 
after a reported spill, we modified the protocol as follows: after a spill occurred and cleanup 
activities, patient care needs, and institutional procedures were completed, participants 
completed the questionnaire described above. Next, participants obtained a urine sampling 
Friese et al. Page 3













kit located in an office several hundred yards from the infusion area. Each kit was housed in 
16 quart thermal insulated cooler and contained: written instructions for specimen collection 
and storage, a single-use 500 mL Nalgene® widemouth container, 6 instant ice packs, 2 
castille soap packets, a specimen label, and sharpie pen. Participants labeled the container 
with their unique study identifier and saved all urine for a total of 8 hours. They began their 
urine collection 4 hours after drug exposure occurred. This timeframe was selected to 
optimize the potential amount of drug in the urine and yet avoid the risk of dilution.16 
Participants returned the kit the following day for sample processing.
In addition to the samples collected after a drug spill, we obtained urine samples from 8 
participants who were cancer center employees that did not experience a drug spill or 
participate in spill cleanup on the day of urine collection. These participants also provided 8 
hours of urine. The procedures for the latter participants were identical to those described 
above, but they did not complete questionnaires. Because they experienced no acute drug 
spill, we standardized urine collection for these participants to begin 4 hours before the end 
of their shift and for the first 4 hours after the end of their shift, for a total of 8 hours. The 
analytical laboratories were blinded to specimen sources.
Using single-use disposable personal protective equipment, research staff pooled and 
aliquotted urine as 5 mL samples, and stored at -70 °C. Drugs of interest were detected by 
liquid chromatography tandem mass spectrometry (LC-MS/MS) based on multiple reaction 
monitoring (MRM) for high sensitivity and specificity. To estimate the drug level of the 
detected compounds using calibration curves, stock solution of each drug was serially 
diluted to provide calibration standards with a concentration range from 1 pg/mL to 10 
ng/mL. The calibration standards were mixed with blank urine samples to mimic the 
biological matrix. The drug concentration in urine was determined based on the respective 
calibration curves.
Retrospective Questionnaire
At the end of the 6-month prospective period where spills were reported and urine was 
collected, all participants were invited to complete a paper questionnaire that examined 
organizational factors hypothesized to influence exposure. Participants returned 
questionnaires to a sealed collection bin or mailed them with a postage-paid envelope. 
Reminder emails were sent monthly to increase response rates.
The following measures were collected: practice environment, workload, safety organizing 
scale, and years of experience. The practice environment was assessed using the previously-
validated Practice Environment Scale of the Nursing Work Index (PES-NWI), modified for 
ambulatory oncology.19 Items were modified from the original PES-NWI to reflect 
ambulatory practice and the use of medical assistants. 23 items across six subscales assess 
the degree to which employees agree the characteristic is present in their work setting: 
collegial relations with physicians; participation in practice affairs; foundations for quality 
care; manager leadership, ability, and support; staffing and resource adequacy, and; medical 
assistant support. Reported Cronbach alphas exceeded 0.80 for all subscales and satisfactory 
model fit was achieved with structural equation modeling.19 Subscales are averaged across a 
5-point Likert scale where 1 = strongly disagree and 5 = strongly agree. Workload was 
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assessed as the number of patients the employee had primary responsibility for on the last 
shift. The Safety Organizing Scale (SOS)20 evaluates behaviors that promote safe care 
delivery. These actions include collecting, analyzing, and disseminating information from 
errors, and conducting proactive checks to minimize harms. Nine items are scored on a 7-
point Likert scale (1= not at all to 7 = to a very great extent). Participants indicated their 
years of clinical experience.
Data Analysis
Prospective survey data from spill reports were analyzed with descriptive statistics. Results 
from urine samples were expressed in three terms: (1) below the limit of detection (LOD), 
(2) exceeds the LOD, and (3) exceeds the lower limit of quantification (LLOQ). The limit of 
detection (LOD) is the lowest detectable drug concentration at which the signal to noise 
ratio exceeds 3. The lower limit of quantification (LLOQ) is the most difficult threshold to 
reach and is the lowest quantifiable concentration above which linear regression can be 
achieved between concentration and peak areas in mass chromatogram. Results that 
exceeded the lower limit of quantification are reported as detected drug levels in ng/mL. 
Results that exceed the limit of detection but do not reach the lower limit of quantification 
are expressed as the number (%) of samples with detectable levels of drug. Retrospective 
questionnaire data were analyzes with two-sample t-tests to compare differences between 
exposed and unexposed workers on organizational factors.
Results
The prospective study had 40 participants who completed informed consent (see Figure 1 for 
a study flow diagram). During the 6-month study period, four unique drug spill events were 
reported, nine participants who were present at the time of the spill completed 
questionnaires, and nine urine specimens were provided after a reported exposure. The 
reported drugs spilled were etoposide, cisplatin, pemetrexed, and docetaxel, with a range in 
volume from 5 to 70 mLs. All spills occurred in the patient care area and all involved the use 
of a closed system transfer device. Three of the 4 spills occurred in the most congested area 
of the infusion center. During the spill, all respondents wore one pair of gloves, no 
respondent wore two pairs of gloves, and 29% wore a single-use disposable gown. Sixty 
percent reported zero or a low level of personal concern about the spill. The mean (SD) 
number of personnel who responded to each spill was 4.2(1.3). None of these events was 
reported using the facility's online risk management software.
Participants could describe the spill in their own words. All reported spills involved loose 
connections between the chemotherapy bag and the intravenous tubing or between the 
tubing and the vascular access device. One spill involved a patient with cognitive 
impairment who may not have understood they were connected to an infusion pump. 
Exposed workers reported assisting in the cleanup of patients and exposed surfaces.
Drug Levels from Obtained Urine Samples
The assays for etoposide, docetaxel, and pemetrexed yielded lower limits of quantification 
(LLOQ) of 0.02, 0.025, and 0.10 ng/mL, respectively. The limit of detection (LOD) was set 
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as signal to noise ratio of 3 in mass chromatogram. Due to pre-existing capabilities, 
pemetrexed and docetaxel assays were performed at one laboratory and etoposide assays 
were performed at a second laboratory. Because cisplatin cannot be detected directly by 
using LC-MS/MS electrospray ionization mass spectrometry techniques21 samples were not 
analyzed for this compound.
Table 1 shows the results of the LC-MS/MS analyses. Each table row reports the findings 
from either a worker who was present at the time a specific drug was spilled (labeled by the 
drug spilled) or a participant who provided urine after completing a shift without a drug 
spill. Urine from 6 workers who reported etoposide exposure and 2 samples from 
participants who did not have a spill were analyzed for etoposide. Of the 6 urine samples 
from workers who reported etoposide exposure, 1 sample exceeded the limit of detection 
(LOD), but not the lower limit of quantification (LLOQ). The samples from workers without 
a reported drug spill did not yield detectable levels of etoposide. Of the 3 samples analyzed 
from workers with exposure to docetaxel, pemetrexed, and cisplatin, all were above the 
LOD for docetaxel and no samples were above the LOD for pemetrexed. All three of these 
samples exceeded the LLOQ and were expressed as drug levels: 0.58, 0.10, and 0.03 ng/mL. 
Four samples from workers who did not report a drug spill were above the LOD for 
docetaxel, but not above the LLOQ.
Retrospective Survey Findings
At the end of the 6-month period were spills were reported and urine was collected 
(prospective study phase), 19 of the 40 consented participants (47.5%) completed the 
retrospective questionnaire. All respondents were nursing personnel; no pharmacy personnel 
responded. Table 2 evaluates differences between participants who reported and did not 
report a spill. Compared with workers who did not report a spill, those who reported a spill 
scored significantly lower on the collegial relations with physicians subscale (4.42 vs. 3.21, 
respectively, p = .03). Compared with non-exposed participants, workers who a spill had 
lower scores on the remaining practice environment subscales, higher workloads, lower 
scores on the safety organizing scale, and more years of experience, yet these differences did 
not reach statistical significance.
The study findings prompted practice changes at the participating institution. The 
investigators amended the scientific protocol with the approval of the institutional review 
boards to disclose study results in aggregate to participants. The team met face-to-face with 
the infusion department staff and institutional leadership, where study results, safe handling 
procedures, institutional policies, and the availability of medical surveillance were reviewed. 
After dissemination, staff members have increased their use of double gloves when handling 
ADs. The institution discontinued the practice of reusing impermeable gowns and changed 
equipment after staff feedback. Currently, the institution is reviewing policies, procedures, 
and intravenous tubing and connector selection. Additional quality improvement activities 
regarding patient assignments, infusion scheduling, and cleaning procedures are underway.
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In this single-site, practice-based pilot study of antineoplastic drug exposure in the 
ambulatory oncology setting, 4 spills were reported to the study team, all of which involved 
a hazardous drug.7 An important finding of this study showed that a single drug spill 
exposed multiple workers simultaneously. With the exception of pemetrexed, the drugs 
reported are used frequently in ambulatory oncology settings. The findings suggest that low, 
but quantifiable levels of the tested drugs are found in health care workers soon after a spill. 
Nor is exposure limited exclusively to drug spills. Urine samples from cancer center 
employees who did not report a drug spill had detectable, but no quantifiable levels of 
docetaxel. The mostly likely explanation for this finding is contamination of surfaces in the 
infusion area. The findings from those who did and did not report a drug spill suggests that 
drug spills pose a greater exposure risk to health care workers than routine environmental 
exposure. Yet is it important for health care workers to understand that antineoplastic drug 
exposure occurs in the context of both acute spills and routine drug handling events.
Across a 6-week period with 9,762 drug handling events, Connor and colleagues16 reported 
29 spills or splashes. Over the 6-month study period with 19,284 antineoplastic drugs 
dispensed, 4 spills were reported by nursing personnel. This suggests a lower spill rate than 
published previously in a multi-site study where individual personnel were provided with 
drug handling diaries.16 There is no standard measurement approach for drug spills. Self-
report of drug spills is prone to inherent bias that cannot be overcome without direct, 
continuous practice observation and/or visual recording. The number of drug spills reported 
in the study is a low estimate due to underreporting and restriction to consented participants.
Two participants with quantifiable levels of docetaxel reported spills involving drugs other 
than docetaxel. The facility's latest surface swipe testing report identified docetaxel 
contamination. During spill cleanup, the participants may have also come in contact with 
surfaces contaminated with docetaxel. As personal protective equipment use was low by 
study participants, these workers may have handled docetaxel during their shift without 
adequate protection. It is unlikely docetaxel was administered concurrently with these 
agents. The structures and molecular weights of paclitaxel and docetaxel differ enough to 
eliminate the possibility of errant findings using LC-MS/MS.22 Pre-existing surface 
contamination with docetaxel likely explains these findings. Surface swipe test monitoring 
and thorough cleaning of affected surfaces are necessary to reduce environmental exposure.
The participating facility had devoted significant resources for training, supplies, and 
medical monitoring. Considering the high frequency of unintentional drug exposure reported 
previously,18 the current findings are conservative. This only highlights the need for 
strategies to reduce exposure through environmental modifications and worker adherence to 
practice guidelines.
We found modest support for a relationship between organizational factors and AD 
exposure. Nurses who reported drug spills reported significantly less favorable relationships 
with physicians. Similar trends were observed across other organizational factors, though no 
other differences were statistically significant. Collegial nurse-physician relationships may 
Friese et al. Page 7













serve as a proxy for stronger teamwork, which has documented importance on a variety of 
safety behaviors.23 It is possible, though untested, that organizational factors must be 
favorable to assure adequate adherence to recommended guidelines and heightened 
situational awareness.
Limitations
Despite initial receptivity, pharmacy personnel had low participation rates for unclear 
reasons. The pharmacy physical location and access restrictions limited the ability of study 
staff to visit to review study procedures and answer questions. The absence of a pharmacist 
on the study team and low perceived exposure risk are additional explanations. This study 
was conducted in one facility with a relatively small sample, which limits the 
generalizability of findings. The absence of statistically-significant differences in the 
retrospective survey are likely due to this small sample size and warrant confirmation in a 
larger, multi-site study. It is likely that non-responders to the retrospective survey have 
differing perceptions than responders. Finally, our LC-MS/MS procedures were performed 
at two different labs due to pre-existing capabilities. To increase the reliability of biological 
measures, we recommend all samples be processed for all antineoplastic drugs by one 
laboratory, followed by independent confirmation by a second laboratory. Finally, the 
survey findings would be strengthened by baseline collection of survey measures to examine 
work environments, workloads, and safety behaviors before drug spills are measured. These 
limitations are presented alongside one of the few published prospective investigations of 
antineoplastic drug spills and organizational factors in an ambulatory oncology setting.
Conclusions and Implications
Our findings have important implications for clinicians, practice leaders, and researchers. 
Detectable levels of drugs are found in both the presence and absence of acute drug spills. 
This finding suggests increased vigilance by staff is warranted throughout the drug 
preparation, administration, and disposal process. Drug spills pose a significant threat to 
workers, and increased efforts are needed to minimize worker exposure through strict 
adherence to published guidelines. These efforts should include structural (e.g., closed 
system transfer devices), individual (e.g., personal protective equipment adoption), and 
behavioral (e.g., heightened situational awareness) approaches.8-10 The 2013 ASCO/ONS 
revisions to chemotherapy safety standards discuss necessary safe handling education and 
instruction.24 The challenge is how to implement these recommendations and optimize 
worker protection.
Intravenous tubing connections are a significant contributor to chemotherapy spills. This 
finding should alert practice managers and clinicians to review products carefully for 
suitability for hazardous drug preparation and administration. Staff should participate 
actively in selecting personal protective equipment that balances comfort and safety. 
Practice leaders must promote a culture of safety and blame-free reporting of spills; 
incidents should be viewed as learning opportunities. As multiple employees were involved 
in spills, educational efforts should evolve to practical team-based case study approaches.
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Several quality improvement opportunities are available. Practices can design and evaluate 
initiatives to promote recommended use of personal protective equipment. Audit and 
feedback programs on drug spills and surface contamination reports can target areas and 
activities at higher risk. Collaborative efforts can share optimal strategies to protect workers 
and maintain clinical efficiency.
Finally, prospective research studies that evaluate biological hazardous drug exposure are 
feasible and yield important insights. Future research efforts should focus on intervention 
development and evaluation, multi-site studies to compare exposures by organizational 
factors, and studies that correlate exposure to health outcomes. These approaches will 
generate the necessary evidence to address a thirty-year old problem.
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Table 1
Antineoplastic Drug Concentrations Urine Samples
Etoposide Docetaxel Pemetrexed
Lower Limit of Quantification 0.02 ng/mL 0.025 ng/mL 0.1 ng/mL
Sample Analyzed Drug Concentration (ng/mL)
Reported Etoposide Spill #1 + N/A N/A
Reported Etoposide Spill #2 - N/A N/A
Reported Etoposide Spill #3 - N/A N/A
Reported Etoposide Spill #4 - N/A N/A
Reported Etoposide Spill #5 - N/A N/A
Reported Etoposide Spill #6 - N/A N/A
No Spill Reported Sample #1 - N/A N/A
No Spill Reported Sample #2 - N/A N/A
Pemetrexed Spill N/A 0.58 -
Docetaxel Spill N/A 0.10 -
Cisplatin Spill N/A 0.03 -
No Spill Reported Sample #3 N/A + -
No Spill Reported Sample #4 N/A + -
No Spill Reported Sample #5 N/A + -
No Spill Reported Sample #6 N/A + -
No Spill Reported Sample #7 N/A - -
No Spill Reported Sample #8 N/A - -
+
Sample exceeds level of detection threshold, but is below the lower limit of quantification (LLOQ). Quantitative values in the table represent 
samples that exceed both level of detection and the lower limit of quantification.
-
Below the limit of detection (signal to noise ratio < 3)
N/A: Not analyzed.
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Table 2
Organizational Factors and Reported Antineoplastic Drug Exposure (n=19)
Variable Antineoplastic Drug Spill Reported P
Yes (n=8) No (n=11)
Mean (SD)
PES-NWI subscales, revised for ambulatory oncology
Collegial relations with physicians 3.21 (1.25) 4.42 (0.56) .03
Participation in practice affairs 4.23 (0.85) 4.69 (0.67) .20
Manager leadership and ability 4.83 (0.31) 4.91 (0.75) .74
Foundations for quality of care 4.29 (0.98) 5.44 (0.55) .14
Supportive relations with medical assistants 4.88 (0.74) 4.45 (1.23) .38
Number of patients on last shift, personally administered chemotherapy 9.88 (0.34) 8.90 (3.83) .49
Safety Organizing Scale score 4.81 (1.21) 5.34 (0.70) .20
Years of experience 18.3 (15.50) 13.7 (9.68) .41
PES-NWI: Practice Environment Scale of the Nursing Work Index
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